Is heparin treatment the optimal management for cerebral venous thrombosis? Effect of abciximab, recombinant tissue plasminogen activator, and enoxaparin in experimentally induced superior sagittal sinus thrombosis

Stroke

Volumn 36, Issue 4, 2005, Pages 841-846

  Röttger, Carina ^a   Madlener, Katharina ^b   Heil, Matthias ^c   Gerriets, Tibo ^a   Walberer, Maureen ^a   Wessels, Tiemo ^a   Bachmann, Georg ^b   Kaps, Manfred ^a   Stolz, Erwin ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Magnetic resonance imaging; Rats; Venous thrombosis

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTICOAGULANT AGENT; ENOXAPARIN; FERRIC CHLORIDE; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BRAIN ANGIOGRAPHY; BRAIN EDEMA; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DRUG EFFECT; EXPERIMENTAL MODEL; FOLLOW UP; FUNCTIONAL ASSESSMENT; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MOTOR PERFORMANCE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SUPERIOR SAGITTAL SINUS; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANGIOGRAPHY; ANIMALS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; EDEMA; ENOXAPARIN; FERRIC COMPOUNDS; HEPARIN; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FAB FRAGMENTS; INTRACRANIAL EMBOLISM AND THROMBOSIS; MAGNETIC RESONANCE IMAGING; MALE; RATS; RECOMBINANT PROTEINS; SAGITTAL SINUS THROMBOSIS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 16844368554     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000157663.43209.a2     Document Type: Article

References (30)

1. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.
2. Schwarz S, Daffertshofer M, Schwarz T, Georgiadis D, Baumgartner RW, Hennerici M, Groden C. [Current controversies in the diagnosis and management of cerebral venous and dural sinus thrombosis]. Nervenarzt. 2003;74:639-653.
3. Canhao P, Falcao F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis. 2003;15:159-166.
4. Niessen F, Hilger T, Hoehn M, Hossmann KA. Thrombolytic treatment of clot embolism in rat: comparison of intra-arterial and intravenous application of recombinant tissue plasminogen activator. Stroke. 2002;33: 2999-3005.
5. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46:561-565.
6. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-108.
7. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88:907-914.
8. Yang Y, Li Q, Nakada MT, Yang T, Shuaib A. Angiographic evaluation of middle cerebral artery reperfusion caused by platelet glycoprotein IIb/IIIa receptor complex antagonist murine 7E3 F(ab′)2 in a model of focal cerebral ischemia in rats. J Neurosurg. 2001;94:582-588.
9. Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma. 1994;11:187-196.
10. Ito K, Tsugane R, Ikeda A, Suzuki Y, Sato K. Cerebral hemodynamics and histological changes following acute cerebral venous occlusion in cats. Tokai J Exp Clin Med. 1997;22:83-93.
11. Rother J, Waggie K, van Bruggen N, de Crespigny AJ, Moseley ME. Experimental cerebral venous thrombosis: evaluation using magnetic resonance imaging. J Cereb Blood Flow Metab. 1996;16:1353-1361.
12. Fries G, Wallenfang T, Kempski O, Hennen J, Velthaus M, Perneczky A. Brain oedema and intracranial pressure in superior sagittal sinus balloon occlusion. An experimental study in pigs. Acta Neurochir Suppl (Wien). 1990;51:231-232.
13. Baumgartner RW, Studer A, Arnold M, Georgiadis D. Recanalisation of cerebral venous thrombosis. J Neurol Neurosurg Psychiatry. 2003;74: 459-461.
14. Stolz E, Trittmacher S, Rahimi A, Gerriets T, Rottger C, Siekmann R, Kaps M. Influence of recanalization on outcome in dural sinus thrombosis: a prospective study. Stroke. 2004;35:544-547.
15. Bianchi D, Maeder P, Bogousslavsky J, Schnyder P, Meuli RA. Diagnosis of cerebral venous thrombosis with routine magnetic resonance: an update. Eur Neurol. 1998;40:179-190.
16. Ayanzen RH, Bird CR, Keller PJ, McCully FJ, Theobald MR, Heiserman JE. Cerebral MR venography: normal anatomy and potential diagnostic pitfalls. Am J Neuroradiol. 2000;21:74-78.
17. Kempski O, Seiwert T, Otsuka H, Heimann A, Nakase H. Modeling of the ischemic penumbra. Acta Neurochir Suppl (Wien). 1999;73:41-44.
18. Tsai FY, Wang AM, Matovich VB, Lavin M, Berberian B, Simonson TM, Yuh WT. MR staging of acute dural sinus thrombosis: correlation with venous pressure measurements and implications for treatment and prognosis. Am J Neuroradiol. 1995;16:1021-1029.
19. Lovblad KO, Bassetti C, Schneider J, Ozdoba C, Remonda L, Schroth G. Diffusion-weighted MRI suggests the coexistence of cytotoxic and vasogenic oedema in a case of deep cerebral venous thrombosis. Neuroradiology. 2000;42:728-731.
20. Chu K, Kang DW, Yoon BW, Roh JK. Diffusion-weighted magnetic resonance in cerebral venous thrombosis. Arch Neurol. 2001;58: 1569-1576.
21. Ducreux D, Oppenheim C, Vandamme X, Dormont D, Samson Y, Rancurel G, Cosnard G, Marsault C. Diffusion-weighted imaging patterns of brain damage associated with cerebral venous thrombosis. Am J Neuroradiol. 2001;22:261-268.
22. Röttger C, Trittmacher S, Gerriets T, Blaes F, Kaps M, Stolz E. Reversible MRI abnormalities following cerebral venous thrombosis. Am J Neuroradiol. 2005;In press.
23. Peeters E, Stadnik T, Bissay F, Schmedding E, Osteaux M. Diffusion-weighted MR imaging of an acute venous stroke: case report. Am J Neuroradiol. 2001;22:1949-1952.
24. Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597-600.
25. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484-488.
26. Frerichs KU, Deckert M, Kempski O, Schurer L, Einhaupl K, Baethmann A. Cerebral sinus and venous thrombosis in rats induces long-term deficits in brain function and morphology - evidence for a cytotoxic genesis. J Cereb Blood Flow Metab. 1994;14:289-300.
27. Overgaard K, Sereghy T, Pedersen H, Boysen G. Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuro-Report. 1992;3:925-928.
28. Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R. Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke. 2003;34:2975-2979.
29. Alexander LF, Yamamoto Y, Ayoubi S, al Mefty O, Smith RR. Efficacy of tissue plasminogen activator in the lysis of thrombosis of the cerebral venous sinus. Neurosurgery. 1990;26:559-564.
30. Hawthorne CO. An address on the cerebral and ocular complications of anaemia and probable relationships of these to thrombosis (1908). Lancet. 2004;857-863.